NUVL
Nuvalent, Inc.Healthcare·Biotechnology
$110.39
$8.1B market cap
Revenue
$0.0M
Free Cash Flow
$-165.7M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibito
2-Year Price History
$102.12+55.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -119.4 | -119.4 | -109.3 | -92.4 | -92.4 | -0.0 | 1,287 | 0.0 | 78.7 | -146.8% | -9.3x | -- |
| Act | 2025-Q4 | 0.0 | -16.3 | -102.2 | -118.7 | -73.3 | -73.3 | -0.0 | 1,372 | 0.0 | 75.1 | -100.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$110.39
Market Cap$8.1B
Enterprise Value$6.8B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-228.0M
Free Cash Flow$-165.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-123.8%
WC Change % Rev0.0%
Interest Coverage-10.6x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.1M
Days to Cover8.3
Change (vs Prior)+10.3%
Need at least 2 settlement dates for chart
Employees
Headcount162
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
91.8%(+33.8% YoY)
242 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
19.2%(+8.9% YoY)
12 filers
Vanguard, iShares, SPDR
Market makers
0.2%(+0.1% YoY)
8 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $1.77B | $29.78 | +$0 | −$76.1M | -3.4% | $7.18B |
| FMR LLC | $950M | $71.32 | −$162M | −$67.8M | -0.0% | $1.89T |
| Paradigm Biocapital Advisors LP | $545M | $67.58 | +$5.6M | +$5.6M | +1.9% | $4.69B |
| BlackRock, Inc.Passive | $494M | $99.25 | +$2.0M | +$110M | -0.2% | $5.69T |
| JPMORGAN CHASE & CO | $299M | $89.58 | +$90.5M | +$289M | -0.2% | $1.47T |
| RA CAPITAL MANAGEMENT, L.P. | $260M | $93.98 | +$67.0M | +$260M | -4.4% | $9.44B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $256M | $102.45 | +$256M | +$256M | — | $1.91T |
| WELLINGTON MANAGEMENT GROUP LLP | $253M | $67.90 | +$888K | +$105M | -0.3% | $533.98B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $249M | $102.45 | +$249M | +$249M | — | $4.04T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $211M | $68.79 | −$9.3M | +$62.0M | -0.2% | $864.93B |
| STATE STREET CORPPassive | $209M | $61.17 | +$17.5M | +$62.0M | -0.2% | $2.89T |
| Polar Capital Holdings Plc | $188M | $89.18 | +$30.2M | +$90.6M | +1.5% | $22.76B |
| PERCEPTIVE ADVISORS LLC | $162M | $64.82 | −$8.7M | −$5.5M | -1.7% | $5.05B |
| T. Rowe Price Investment Management, Inc. | $145M | $81.20 | +$9.6M | +$98.6M | -1.3% | $145.22B |
| Deep Track Capital, LP | $141M | $94.08 | +$113M | +$141M | -1.2% | $4.85B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $133M | $70.42 | +$6.1M | +$41.5M | +2.3% | $1.61T |
| JANUS HENDERSON GROUP PLC | $127M | $75.06 | −$26.8M | −$7.4M | +1.2% | $209.29B |
| Bellevue Group AG | $108M | $100.62 | +$1.6M | +$108M | -4.3% | $4.20B |
| Commodore Capital LP | $85.4M | $60.82 | +$29.1M | −$105M | -0.6% | $1.73B |
| ALLIANCEBERNSTEIN L.P. | $78.9M | $96.58 | −$146K | +$74.9M | -0.3% | $307.70B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.41%
avg per quarter
Holders (ex-self)
-1.08%
excl. this stock
Buyers (this Q)
-0.90%
158 buyers · $1.19B in
Sellers (this Q)
-0.07%
74 sellers · $0.30B out
alpha coverage: 93% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+41.9%
how holders react when this stock falls
On quiet Qs
-1.2%
−10% to +10% baseline
On rallies (+10%+)
+12.0%
how they react when this stock rises
Holders' portfolio flow this Q
+2.1%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.4%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.1%
Holder mid (any stock)
-1.1%
Holder rally (any stock)
-2.9%
Biggest decreases this quarter
FMR LLC−$162Mα-0.0Fairmount Funds Management LLCexited−$73.2MJANUS HENDERSON GROUP PLC−$26.8Mα+1.2BAKER BROS. ADVISORS LPexited−$14.5MBRAIDWELL LP−$12.4Mα-1.7PRICE T ROWE ASSOCIATES INC /MD/−$9.3Mα-0.2Point72 Asset Management, L.P.exited−$8.9MPERCEPTIVE ADVISORS LLC−$8.7Mα-1.7Verition Fund Management LLCexited−$7.2MGOLDMAN SACHS GROUP INC−$5.9Mα-0.2
New buyers this quarter
Top-5 holders · 48.9%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)--
FMR LLC--
Paradigm Biocapital Advisors LP--
BlackRock, Inc.--
JPMORGAN CHASE & CO--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)17.2MFMR LLC9.3MParadigm Biocapital Advisors LP5.3MPERCEPTIVE ADVISORS LLC1.6MJPMORGAN CHASE & CO3.1MBain Capital Life Sciences Investors, LLC—RA CAPITAL MANAGEMENT, L.P.2.5MWELLINGTON MANAGEMENT GROUP LLP2.5MPRICE T ROWE ASSOCIATES INC /MD/2.1MJANUS HENDERSON GROUP PLC1.2M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | 6 | 149.93× |
| TARS | Tarsus Pharmaceuticals, Inc. | 3 | 127.44× |
| RLAY | Relay Therapeutics, Inc. | 4 | 121.37× |
| TYRA | Tyra Biosciences, Inc. | 4 | 121.37× |
| ALKS | Alkermes plc | 4 | 106.20× |
| AMLX | Amylyx Pharmaceuticals, Inc. | 4 | 106.20× |
| CNTA | Centessa Pharmaceuticals plc | 6 | 101.95× |
| ELVN | Enliven Therapeutics, Inc. | 4 | 99.95× |
| DNTH | Dianthus Therapeutics, Inc. | 6 | 98.03× |
| ERAS | Erasca, Inc. | 4 | 94.40× |
| ORKA | Oruka Therapeutics, Inc. | 4 | 94.40× |
| PCVX | Vaxcyte, Inc. | 5 | 88.50× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (12 analysts)$132.832030.0%
Current Price$110.39
Analyst Ratings
14
Buy: 14Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$76.81M
75 txns · 7 insiders · 824,212 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$35.44M
1 txn · 1 insider · 371,287 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | SELL | Porter James Richard | director, officer: President and CEO | 30,000 | $101.69 | $3.05M | $33.04M |
| 2026-05-01 | SELL | Balcom Alexandra | officer: Chief Financial Officer | 11,430 | $99.00 | $1.13M | $8.47M |
| 2026-04-30 | SELL | Miller Deborah Ann | officer: Chief Legal Officer | 5,500 | $99.22 | $546K | $5.92M |
| 2026-04-29 | SELL | Noci Darlene | officer: Chief Development Officer | 5,500 | $99.55 | $548K | $5.79M |
| 2026-04-09 | SELL | Pelish Henry E. | officer: Chief Scientific Officer | 3,093 | $104.48 | $323K | $6.85M |
| 2026-04-06 | SELL | Porter James Richard | director, officer: President and CEO | 30,000 | $103.77 | $3.11M | $33.71M |
| 2026-04-01 | SELL | Balcom Alexandra | officer: Chief Financial Officer | 11,430 | $105.21 | $1.20M | $9.00M |
| 2026-03-30 | SELL | Noci Darlene | officer: Chief Development Officer | 5,500 | $97.81 | $538K | $5.68M |
| 2026-03-26 | SELL | Miller Deborah Ann | officer: Chief Legal Officer | 5,500 | $98.73 | $543K | $5.89M |
| 2026-03-25 | SELL | Balcom Alexandra | officer: Chief Financial Officer | 13,700 | $100.16 | $1.37M | $8.57M |
| 2026-03-24 | SELL | Balcom Alexandra | officer: Chief Financial Officer | 11,430 | $95.75 | $1.09M | $9.50M |
| 2026-03-13 | SELL | Pelish Henry E. | officer: Chief Scientific Officer | 5,104 | $98.98 | $505K | $6.49M |
| 2026-03-12 | SELL | Pelish Henry E. | officer: Chief Scientific Officer | 30,000 | $97.92 | $2.94M | $6.92M |
| 2026-03-06 | SELL | Porter James Richard | director, officer: President and CEO | 30,000 | $98.99 | $2.97M | $32.16M |
| 2026-02-26 | SELL | Miller Deborah Ann | officer: Chief Legal Officer | 5,500 | $103.05 | $567K | $6.15M |
| 2026-02-26 | SELL | Noci Darlene | officer: Chief Development Officer | 5,500 | $103.03 | $567K | $5.99M |
| 2026-01-29 | SELL | Noci Darlene | officer: Chief Development Officer | 5,500 | $102.08 | $561K | $5.93M |
| 2026-01-22 | SELL | Miller Deborah Ann | officer: Chief Legal Officer | 14,300 | $110.16 | $1.58M | $6.57M |
| 2026-01-21 | SELL | Miller Deborah Ann | officer: Chief Legal Officer | 700 | $109.84 | $77K | $6.55M |
| 2026-01-06 | SELL | Turner Christopher Durant | officer: Chief Medical Officer | 3,181 | $97.16 | $309K | $5.36M |
Order Flow (FINRA, ~3w lag)
16.3%retail-1.0pp
35.5%dark+8.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Nuvalent, Inc.: Accelerated Cash Burn and C-Suite Exit Velocity Amid Complex Related-Party Revenue Hooks
Overall Risk
5/10
Fraud
3/10
Dilution
8/10
Insolvency
2/10
Earnings Overstated
4/10
Hidden Liabilities
6/10
Legal
2/10
Audit Warnings
1/10
Hidden Upside
7/10
Contextually Acceptable
7/10